{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.79","value":"-1.0"},{"groupId":"OG001","spread":"2.84","value":"-0.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"97"}],"units":"Participants"}],"description":"Functional Assessment of Cancer Therapy-Ovarian Symptom Index is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants respond to their symptom experience over the past 7 days using a 5-point Likert scale score from \"not at all\" (0) to \"very much\" (4). The total score was calculated by multiplying the sum of all items scored by 8 and dividing the result by the number of responses. The total symptom index was calculated as the total of the 8 scores, ranging from 0 (\"severely symptomatic\") to 32 (\"asymptomatic\"). A positive change from Baseline indicates improvement. Baseline was latest non-missing pre-dose assessment on or before randomization date. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.","dispersionType":"Standard Deviation","groups":[{"description":"Participants without germline BRCA mutation received oral dose of niraparib 300 mg once daily orally in 28-day cycles until disease progression.","id":"OG000","title":"Non-gBRCA Niraparib"},{"description":"Participants without germline BRCA mutation received matching placebo once daily orally in 28-day cycles until disease progression","id":"OG001","title":"Non-gBRCA Placebo"}],"paramType":"MEAN","populationDescription":"Intent-to-treat Population. Only those participants with data available at the indicated time points were analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline (Pre-dose on Day 1) and at Cycle 2 (Each cycle was of 28 days)","title":"Change From Baseline in Functional Assessment of Cancer Therapy-Ovarian Symptom Index in Cohort With no Germline BRCA at Cycle 2","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}